Pharma exports expected to double to $65 billion by 2030: Report
pharma exports are expected to double to USD 65 billion by 2030 and touch USD 350 billion in value terms by 2047, moving to top five position globally by diversifying its product basket, according to a report. While India is the largest supplier of generic drugs globally, accounting for one in five generic drugs sold worldwide, the nation ranks 11th in terms of export value.
Delhi Election Results
Top battlegrounds: What's happening where
D-day for Delhi: Top newsmaking moments
As per the Bain & Company's report, 'Healing the World: Roadmap for Making India a Global Pharma Exports Hub', India can potentially secure a position among the top five nations in export value by 2047 by innovating and diversifying its export basket to include specialty generics, biosimilars, and innovative products.
The findings in the report were formulated in collaboration with Indian Pharmaceutical Alliance (IPA), Indian Drugs Manufacturers' Association (IDMA), and Pharmexcil.
«The transition from volume-based to value-led growth is essential for Indian pharma to secure its rightful place in the global market. Innovation, including the shift towards specialty generics, biosimilars, and novel products, will be the key to India's pharmaceutical future,» Sriram Shrinivasan, Partner, Bain & Company, said.
With the right focus on quality, regulation, access to global markets, talent, and entrepreneurial innovation, India can rise to be among the top-five pharma exporters globally by 2047, he added.
Artificial
